Skip to content

Search Results

No Matching Results

    Recently Viewed


      HomeLatest newsGlassdoor names Johnson & Johnson’s Alex Gorsky a 2018 top CEO
      FINAL LEDE- A Look Back on Our Work in 2019- Alex gorsky dyir digital year in review

      Glassdoor names Johnson & Johnson’s Alex Gorsky a 2018 top CEO

      The Chairman and CEO has now appeared on the Glassdoor list for five years running—all thanks to his employees.

      Share Article
      share to

      How many people can say they love their boss? At Johnson & Johnson, a whole lot of employees can—and do.

      For the fifth year in a row, Alex Gorsky, Chairman of the Board and Chief Executive Officer of Johnson & Johnson, has been named to Glassdoor’s Employees’ Choice Awards list of Top CEOs.

      Glassdoor, one of the world’s largest jobs and recruiting sites, compiles its annual list of best CEOs throughout North America and parts of Europe based solely on employee reviews submitted through its platform—and 95% of staffers who reviewed Johnson & Johnson for the 2018 rankings said they approved of Gorsky’s leadership.

      To help put that into perspective, 770,000 companies were reviewed, and the average CEO approval rating came in at 69%.

      As the seventh Chairman and CEO since the company went public in 1944, Gorsky’s leadership has personified the values of Johnson & Johnson’s Credo—the company’s guiding mission statement, which prioritizes the needs of patients and employees alike—and has helped Johnson & Johnson solidify its position as the largest and most broadly based healthcare company in the world.

      And this isn’t the only accolade the company has recently garnered under Gorsky’s direction: Johnson & Johnson also took the #1 spot on the 2018 DiversityInc Top 50 Companies for Diversity list, and was named a 2018 Fortune World’s Most Admired Company.

      Congratulations to Gorsky on the recognition of his exceptional leadership.

      More from Johnson & Johnson

      Meet a nurse who leads clinical trials to find innovative cancer therapies

      Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.

      What’s the difference between IBS and IBD?

      These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

      What is IL-23?

      This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat autoimmune conditions such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.